BIOMAT Database Logo BIOMAT Database Logo

Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS. 1995

S Jurriaans, and G J Weverling, and J Goudsmit, and J Boogaard, and M Brok, and D Van Strijp, and J Lange, and M Koot, and B Van Gemen
Human Retrovirus Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands.

Serum HIV-1 RNA and p24 antigen levels were examined in 28 seropositive asymptomatic individuals participating in a trial on the efficacy of zidovudine. Sixteen individuals remained asymptomatic until 4 years after the onset of the trial, whereas 12 individuals were diagnosed with an AIDS-defining event. The serum HIV-1 RNA load and p24 antigen levels were determined before the onset of therapy and during the first 8 weeks of therapy to establish whether the patterns of change were predictive of clinical outcome. Among the 28 participants 43% had measurable pretreatment concentrations of p24 antigen. Initiation of zidovudine therapy was followed by a similar decline of p24 antigen levels in nonprogressors as well as progressors and, therefore, these groups could not be distinguished on the basis of this parameter. HIV-1 RNA was detected in the pretreatment samples of 82% of the individuals and could be detected in p24 antigen-positive as well as p24 antigen-negative individuals. Similar changes in HIV-1 RNA load during zidovudine therapy were observed in p24 antigen-positive and -negative individuals. Analysis of the HIV-1 RNA response according to clinical outcome demonstrated that HIV-1 RNA copy numbers had declined significantly after 4 weeks of therapy in both nonprogressors and progressors, but the decline in RNA load was much stronger in the nonprogressors. Our data show that the HIV-1 RNA load in serum can be used to monitor the response to antiviral therapy in p24 antigen-positive as well as -negative individuals. Posttreatment changes in p24 antigen levels are not indicative for clinical outcome, whereas RNA copy numbers are.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA

Related Publications

S Jurriaans, and G J Weverling, and J Goudsmit, and J Boogaard, and M Brok, and D Van Strijp, and J Lange, and M Koot, and B Van Gemen
Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects.
August 1990, The Netherlands journal of medicine,
S Jurriaans, and G J Weverling, and J Goudsmit, and J Boogaard, and M Brok, and D Van Strijp, and J Lange, and M Koot, and B Van Gemen
Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine.
September 1990, AIDS (London, England),
S Jurriaans, and G J Weverling, and J Goudsmit, and J Boogaard, and M Brok, and D Van Strijp, and J Lange, and M Koot, and B Van Gemen
Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.
March 1993, AIDS (London, England),
S Jurriaans, and G J Weverling, and J Goudsmit, and J Boogaard, and M Brok, and D Van Strijp, and J Lange, and M Koot, and B Van Gemen
Serum beta 2-microglobulin levels in asymptomatic HIV-1-infected subjects during long-term zidovudine treatment.
June 1991, Genitourinary medicine,
S Jurriaans, and G J Weverling, and J Goudsmit, and J Boogaard, and M Brok, and D Van Strijp, and J Lange, and M Koot, and B Van Gemen
A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals.
December 1996, Antiviral therapy,
S Jurriaans, and G J Weverling, and J Goudsmit, and J Boogaard, and M Brok, and D Van Strijp, and J Lange, and M Koot, and B Van Gemen
Reduction of p24 antigen levels in asymptomatic patients using twice-daily zidovudine.
January 1989, AIDS (London, England),
S Jurriaans, and G J Weverling, and J Goudsmit, and J Boogaard, and M Brok, and D Van Strijp, and J Lange, and M Koot, and B Van Gemen
Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection.
April 1991, Wisconsin medical journal,
S Jurriaans, and G J Weverling, and J Goudsmit, and J Boogaard, and M Brok, and D Van Strijp, and J Lange, and M Koot, and B Van Gemen
Quantification of low levels of human immunodeficiency virus (HIV) type 1 RNA in P24 antigen-negative, asymptomatic, HIV-positive patients by PCR.
February 1996, Journal of clinical microbiology,
S Jurriaans, and G J Weverling, and J Goudsmit, and J Boogaard, and M Brok, and D Van Strijp, and J Lange, and M Koot, and B Van Gemen
Declining levels of HIV P24 antigen in serum during treatment with foscarnet.
May 1988, Lancet (London, England),
S Jurriaans, and G J Weverling, and J Goudsmit, and J Boogaard, and M Brok, and D Van Strijp, and J Lange, and M Koot, and B Van Gemen
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
November 1992, AIDS (London, England),
Copied contents to your clipboard!